A conjugate of manganese-metalloporphyrin and gadolinium (Gd)-diethylenetriaminepenta-acetic acid (Gd-ATN10) was developed as a tumor-specific enhancement agent for magnetic resonance (MR) imag ing. Gd-ATN10 was evaluated in an experimental 9L gliosarcoma rat tumor model. T<SUB>1</SUB>-weighted MR im aging showed enhancement of the tumor which persisted for up to 24 hours. Gd concentration measure ment by inductively coupled plasma atomic emission spectroscopy revealed the peak Gd concentration was reached after 30 minutes and Gd was retained in the blood and tumor up to 24 hours. There was no uptake of Gd in the normal brain and little in the skin. Gd-porphyrin derivatives are potentially useful agents for tumor diagnosis on MR imaging and for neutron capture therapy.
Introduction
Magnetic resonance (MR) imaging frequently in volves the use of gadolinium-diethylenetriaminepen ta-acetic acid (Gd-DTPA) as an enhancement agent. Gd-DTPA accumulates in areas where the blood brain barrier is damaged, but may not be specific to the tumor and is rapidly washed out from the kidney.") Porphyrin derivatives have also been used for pho to-dynamic therapy in cancer") and more recently for diagnosis by scintigraphy,',9) MR imaging 2-') and single photon emission computed tomography10) due to the selective uptake by tumor tissue. Manganese (Mn)-metalloporphyrin derivatives such as Mn tetrakis-(4-sulfonatophenyl) porphyrin which contain paramagnetic Mn within the porphyrin structure have been developed as MR imaging enhancement agents2-5) which are, however, neurotoxic. Gd por phyrin derivatives such as Gd-tetrakis-(N-methyl-4 pyridyl)porphyrin4) and Gd-tetrakis-(4-sulfonato phenyl)porphyrin2°') have been developed as MR im aging enhancement agents, but these are thought to be unstable in vivo.') Gd is known to be unstable if placed directly into the porphyrin cage, 14) and there fore cannot be used safely in patients. A porphyrin derivative incorporating a bifunctional chelating agent outside the porphyrin structure has been developed for scintigraphy',11) and using this tech nique, Gd-DTPA was chemically bound to ATN10 (Gd-ATN10) for use as tumor-specific contrast agent for MR imaging and a potential agent for Gd neu tron capture therapy. 1,12) We describe an initial evaluation of Gd-ATN10 as MR imaging enhance ment agent in a rat glioma model.
Materials and Methods
The DTPA ester of 2-[1-(2-hydroxyethoxy)ethyl]-4 vinyl-deuteroporphyrin (IX) Mn complex (ATN10), a bifunctional chelating agent coupled to por phyrin, was synthesized by a slightly modified method as described elsewhere.") ATN10 was then conjugated to Gd-DTPA anhydride to produce Gd ATN10.
The relaxivities of ATN10 and Gd-ATN10 were measured at 370 C in 0.9% sodium chloride solution in a 10 mm standard nuclear magnetic resonance glass tube using a Minispec PC20 (20 MHz, 0.5 T; Bruker Co., Ltd., Karlsruhe, Germany). The T1 relaxa tion time was calculated by the inversion recovery sequence (repetition time [TR] = 5 sec, with eight different tau values).
Fisher 344 strain rats were used for the experimen tal brain tumor model. 9L glioma cells (1 x 104/10 pl) were inoculated into the brain parenchyma at 5 mm depth from the surface through a burr hole just caudal to the coronal suture using a stereotactic manipulator with a 27 G needle. Fourteen days after the inoculation of the tumor cells, general anesthesia was induced using pentobarbital (30-50 mg/kg) with spontaneous breathing. MR imaging was performed using a superconducting MR system BMT24/40 (2.4 T; Bruker Co., Ltd.) using the spin echo technique to obtain T1-weighted (TR/echo time [TE] = 512/28 msec) and T2-weighted images (TRITE = 2040/80 msec). The enhancement effect of Gd-ATN10 on T1 weighted images was investigated by comparing the signal intensities of the normal brain and the tumor before (n = 11) and 0.5 (n = 3), 1 (n = 7), 6 (n = 4), and 24 (n = 2) hours after intravenous injection of Gd-ATN10 (0.02 mmol/kg). The signal intensity ratio (SI ratio = SI tumor/SI normal brain) was calculated at each time point.
After MR imaging, the rats were sacrificed using an overdose of pentobarbital. Tumor, brain, skin, and serum samples were taken and T1 relaxation time of the brain, tumor, and tumor after Gd-ATN10 injection (0.5, 1, 6, 24, 48 hours) were measured by Minispec PC20 directly after removal and the tissues were frozen for further Gd and Mn concentration measurement. Gd and Mn concentrations in the tis sue were measured using an inductively-coupled plasma atomic emission spectroscopy (SPS 1200A; Seiko Electric Co., Ltd., Chiba).
Results
The relaxivities of ATN10 and Gd-ATN10 showed linear correlations between the concentration of the paramagnetic agents and 1/T1. The relaxivity of Gd ATN10 was stronger than that of ATN10 (Fig. 1) . The relaxivity of Gd-ATN10 is much higher than that of Gd-DTPA, whereas that of ATN10 was about the same order as that of Gd-DTPA.4)
The T1 relaxation time of normal brain measured at 20 MHz was 578 ± 38 msec. The 9L glioma had a longer T1 time than normal brain (781 ± 46 msec), but the T1 time shortened after Gd-ATN10 injection most prominently at 30 minutes after Gd-ATN10 in jection, and then gradually recovered to the control level (Fig. 2) . MR imaging of the rats showed that the tumor was a hypointense mass with a SI ratio of 0.93. After in jection of Gd-ATN10, the tumor became hyperin tense, with peak contrast enhancement (SI ratio of 1.37) at 30 minutes and persisting for more than 24 hours (SI ratio of 1.26) (Fig. 3) . The tumor margin was sharp in the early stage but became slightly diffuse after 6 and 24 hours (Fig. 4A-D) . The enhan cement effect was well correlated with the histologi cal findings (Fig. 4E) . The enhancement effect was dose dependent at 0.01 and 0.02 mmol/kg administra tion.
The concentration of Gd after 0.02 mmol/kg Gd ATN10 injection peaked in the blood at 23,ug/g tis sue after 1 hour, and in the tumor at 9 ,ug/g tissue af ter 30 minutes (Fig. 5) . Gd was present at low concen tration in the skin (peak 4.8 pg/g tissue), but Gd was not detectable in the normal brain (except 0.15 pg/g tissue after 1 hour). The Gd concentration decreased gradually for 24 hours after administration. The mo lar ratio of Gd and Mn in Gd-ATN10 should be 1 based on the structure. Simultaneous Gd and Mn concentration measurement in the tumor revealed that the Gd/Mn molar ratio remained at 0.92 ± 0.34 6 hours after injection but decreased to 0.06 ± 0.1 af ter 24 hours. These data suggest dissociation of the Gd and Mn in the later phase of the experiment. injec tion. The corresponding histological slice is also shown (E). In the early stage of enhan cement the tumor margin is relatively sharp, while after 6 and 24 hours, the margin became slightly diffuse.
Discussion
The present study showed that Gd-ATN10 causes ef fective shortening of T1 relaxation time in tissue, and is selectively accumulated in tumor tissue and not in normal brain, in contrast to other types of Mn metalloporphyrin.5) Although Gd remained up to 24 hours in the tumor, which is longer than for Gd DTPA, this compound may still not be stable enough when retained for a long period in vivo. Although Gd-DTPA has a very high thermodynamic stability constant (logk = 22.46), a small amount of Gd-DTPA will dissociate with a longer retention time in vivo.6'13) This dissociation is thought to be mainly due to the substitution of endogenous metal ions, such as Fe, Cu, and Zn, which possess higher affinity for DTPA than Gd.6) Another possibility is that since Gd DTPA is a pentavalent acid, the stability depends on the pH of the tissue and Gd-DTPA will dissociate with excess H+ in the tissue which occurs in bony matrix.') Such dissociation is not critical clinically because Gd-DTPA is rapidly cleared from the body.') However, for Gd compounds which persist for a longer period in the body, like Gd-porphyrin, a more stable chelating agent is required for safety in clinical use.
Recently, a Gd-DTPA-conjugated porphyrin derivative was developed using tetra-p-aminophenyl porphyrin, which is relatively stable compared to previous Gd-porphyrins.4) This compound is similar to ours in that the porphyrin is conjugated to Gd DTPA and is stabilized because the Gd is chelated. However, it is phototoxic whereas our compound has no phototoxicity,8) which is a major advantage for clinical use.
Another aim for developing Gd-ATN10 is to use this agent for neutron capture therapy.',") Gd has a neutron capture cross section area 66 times greater than boron. The reaction with neutrons produces gamma rays and Auger electrons which may induce selective radiation damage in the enhanced area on MR imaging.
The present study shows that Gd-ATN10 is a poten tial contrast agent for MR imaging and an absorp tion agent for neutron capture therapy. several basic experimental studies were done very carefully. This Gd compound may be used for neutron capture therapy instead of boron compounds') in the future. However, further investigation will be necessa ry for clinical application.
Another important point of this paper is the applica tion to diagnosis of brain tumors. This Gd compound had a high tumor specificity. Tracer kinetic study demonstrated Gd enhancement persisted for up to 24 hours. This finding was quite different from commer cially available Gd containing contrast enhancement agents. This MRI enhancement study was done only in rat transplanted glioma. We recommend further ex perimental studies to clarify whether differential diag nosis is possible with other brain tumors or with radia tion necrosis before clinical application. 
Commentary
Gadolinium (Gd) neutron capture reactions result in emission of gamma rays with the maximal energy of 7.9 MeV followed by a series of secondary gamma rays and 29 to 180 keV internal conversion electrons. 2 Previous experimental studies have demonstrated that both gamma rays and electrons affect the tumor cell survival. As electrons react within a very short dis tance, highly selective irradiation of brain tumors will be possible if neutron capture agents with high tumor specificity are developed. In vivo measurement of tis sue tracer kinetics is possible by shortening of T1 relax ation time in MRI. The authors have developed a new Gd-conjugated agent with high tumor specificity and
